VA study spotlights higher death rate among Covid-19 patients treated with the controversial drug hydroxychloroquine
Just weeks following the FDA’s emergency approval of hydroxychloroquine after President Trump repeatedly advocated its use for Covid-19, new data from a quick VA study highlighted an added risk of death with the drug.
Drawing on the retrospective analysis of outcomes of 368 male VA patients, investigators concluded that patients taking hydroxychloroquine — a malaria drug — had a 27.8% death rate, well over twice the 11.4% death rate in the group who were not treated with hydroxychloroquine. The arm using hydroxychloroquine alone had a slightly higher rate of death than the 22.1% who were treated with hydroxychloroquine plus azithromycin, but that relatively small difference could have been triggered by other factors
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.